Hale family gives $100 million to Brigham and Women’s and Boston Children’s

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Boston Children’s Hospital and Brigham and Women’s Hospital received gifts of $50 million each from Rob and Karen Hale and their family to support innovation and patient care.

Karen and Rob Hale are Boston-area philanthropists with ties to BWH and BCH. Karen serves on BWH’s Cancer Advisory Board and Rob, who is CEO of Quincy-based Granite Telecommunications, serves as a chair of BWH’s $1.5 billion Life.Giving.Breakthroughs. campaign, as well as on the Steering Committee for Boston Children’s Dream, Dare, Deliver campaign.

In recognition of the gift, BWH will name their recently opened building the Hale Building for Transformative Medicine. The building houses the Ann Romney Center for Neurologic Diseases; the Evergrande Center for Immunologic Diseases; The Gillian Reny Stepping Strong Center for Trauma Innovation; The Neurosciences Center; the Orthopaedics and Arthritis Center, and the Brigham Innovation Hub.

The building is also home to an infusion suite and imaging center featuring technologies such as a 7 Tesla MRI, the first to be installed in a clinical setting in North America.

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login